126 related articles for article (PubMed ID: 25954816)
1. Pioglitazone increases whole body insulin sensitivity in obese, insulin-resistant rhesus monkeys.
Tozzo E; Bhat G; Cheon K; Camacho RC
PLoS One; 2015; 10(5):e0126642. PubMed ID: 25954816
[TBL] [Abstract][Full Text] [Related]
2. Phenotyping of adipose, liver, and skeletal muscle insulin resistance and response to pioglitazone in spontaneously obese rhesus monkeys.
Shang J; Previs SF; Conarello S; Chng K; Zhu Y; Souza SC; Staup M; Chen Y; Xie D; Zycband E; Schlessinger K; Johnson VP; Arreaza G; Liu F; Levitan D; Wang L; van Heek M; Erion M; Wang Y; Kelley DE
Am J Physiol Endocrinol Metab; 2017 Apr; 312(4):E235-E243. PubMed ID: 28143858
[TBL] [Abstract][Full Text] [Related]
3. Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment.
Ciaraldi TP; Aroda V; Mudaliar SR; Henry RR
Metabolism; 2013 Nov; 62(11):1587-96. PubMed ID: 23958241
[TBL] [Abstract][Full Text] [Related]
4. Chronic treatment with pioglitazone does not protect obese patients with diabetes mellitus type II from free fatty acid-induced insulin resistance.
Serlie MJ; Allick G; Groener JE; Ackermans MT; Heijligenberg R; Voermans BC; Aerts JM; Meijer AJ; Sauerwein HP
J Clin Endocrinol Metab; 2007 Jan; 92(1):166-71. PubMed ID: 17062758
[TBL] [Abstract][Full Text] [Related]
5. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
6. Pioglitazone treatment enhances the sympathetic nervous system response to oral carbohydrate load in obese individuals with metabolic syndrome.
Straznicky NE; Grima MT; Sari CI; Eikelis N; Lambert GW; Nestel PJ; Richards K; Dixon JB; Schlaich MP; Lambert EA
Metabolism; 2015 Jul; 64(7):797-803. PubMed ID: 25827058
[TBL] [Abstract][Full Text] [Related]
7. Diet/Exercise versus pioglitazone: effects of insulin sensitization with decreasing or increasing fat mass on adipokines and inflammatory markers.
Shadid S; Stehouwer CD; Jensen MD
J Clin Endocrinol Metab; 2006 Sep; 91(9):3418-25. PubMed ID: 16804048
[TBL] [Abstract][Full Text] [Related]
8. Pioglitazone treatment enlarges subcutaneous adipocytes in insulin-resistant patients.
Koenen TB; Tack CJ; Kroese JM; Hermus AR; Sweep FC; van der Laak J; Stalenhoef AF; de Graaf J; van Tits LJ; Stienstra R
J Clin Endocrinol Metab; 2009 Nov; 94(11):4453-7. PubMed ID: 19820024
[TBL] [Abstract][Full Text] [Related]
9. Pioglitazone increases non-esterified fatty acid clearance in upper body obesity.
Shadid S; Jensen MD
Diabetologia; 2006 Jan; 49(1):149-57. PubMed ID: 16323003
[TBL] [Abstract][Full Text] [Related]
10. Impaired insulin-stimulated phosphorylation of Akt and AS160 in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment.
Højlund K; Glintborg D; Andersen NR; Birk JB; Treebak JT; Frøsig C; Beck-Nielsen H; Wojtaszewski JF
Diabetes; 2008 Feb; 57(2):357-66. PubMed ID: 17977950
[TBL] [Abstract][Full Text] [Related]
11. Prior thiazolidinedione treatment preserves insulin sensitivity in normal rats during acute fatty acid elevation: role of the liver.
Ye JM; Frangioudakis G; Iglesias MA; Furler SM; Ellis B; Dzamko N; Cooney GJ; Kraegen EW
Endocrinology; 2002 Dec; 143(12):4527-35. PubMed ID: 12446579
[TBL] [Abstract][Full Text] [Related]
12. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.
Miyazaki Y; Mahankali A; Wajcberg E; Bajaj M; Mandarino LJ; DeFronzo RA
J Clin Endocrinol Metab; 2004 Sep; 89(9):4312-9. PubMed ID: 15356026
[TBL] [Abstract][Full Text] [Related]
13. Effects of pioglitazone on hepatic and peripheral insulin resistance in Wistar fatty rats.
Sugiyama Y; Shimura Y; Ikeda H
Arzneimittelforschung; 1990 Apr; 40(4):436-40. PubMed ID: 2192715
[TBL] [Abstract][Full Text] [Related]
14. Pioglitazone increases gallbladder volume in insulin-resistant obese mice.
Al-Azzawi HH; Mathur A; Lu D; Swartz-Basile DA; Nakeeb A; Pitt HA
J Surg Res; 2006 Dec; 136(2):192-7. PubMed ID: 17045610
[TBL] [Abstract][Full Text] [Related]
15. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
Miyazaki Y; Mahankali A; Matsuda M; Mahankali S; Hardies J; Cusi K; Mandarino LJ; DeFronzo RA
J Clin Endocrinol Metab; 2002 Jun; 87(6):2784-91. PubMed ID: 12050251
[TBL] [Abstract][Full Text] [Related]
16. Enhanced granulosa cell responsiveness to follicle-stimulating hormone during insulin infusion in women with polycystic ovary syndrome treated with pioglitazone.
Coffler MS; Patel K; Dahan MH; Yoo RY; Malcom PJ; Chang RJ
J Clin Endocrinol Metab; 2003 Dec; 88(12):5624-31. PubMed ID: 14671144
[TBL] [Abstract][Full Text] [Related]
17. Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome.
Ortega-González C; Cardoza L; Coutiño B; Hidalgo R; Arteaga-Troncoso G; Parra A
J Endocrinol; 2005 Jan; 184(1):233-9. PubMed ID: 15642799
[TBL] [Abstract][Full Text] [Related]
18. Insulin resistance in obesity can be reliably identified from fasting plasma insulin.
ter Horst KW; Gilijamse PW; Koopman KE; de Weijer BA; Brands M; Kootte RS; Romijn JA; Ackermans MT; Nieuwdorp M; Soeters MR; Serlie MJ
Int J Obes (Lond); 2015 Dec; 39(12):1703-9. PubMed ID: 26155920
[TBL] [Abstract][Full Text] [Related]
19. Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment.
Glintborg D; Højlund K; Andersen M; Henriksen JE; Beck-Nielsen H; Handberg A
Diabetes Care; 2008 Feb; 31(2):328-34. PubMed ID: 18000176
[TBL] [Abstract][Full Text] [Related]
20. Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555.
Upton R; Widdowson PS; Ishii S; Tanaka H; Williams G
Br J Pharmacol; 1998 Dec; 125(8):1708-14. PubMed ID: 9886762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
